Managing Drugs and Devices in Patients with Permanent Ventricular Assist Devices

Overview

Journal Curr Treat Options Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2007 Sep 1

PMID 17761117

Authors

Martin Cadeiras

Manuel von Bayern

Mario C Deng

Affiliations

Soon will be listed here.

Abstract

Patients will be considered for destination mechanical circulatory support device (MCSD) implantation when all other organ-saving treatment options have failed and they are not eligible for heart transplantation. Current medical evidence suggests that only for those patients who are inotrope-dependent and therefore likely have a 1-year survival probability without MCSD implantation of less than 50%, MCSD intervention will add to survival and quality-of-life benefit. Suitable candidates for MCSD are those patients who have a high risk of dying from heart failure but acceptable noncardiac risk. Evaluation of patients for MCSD requires a systematic and critical review of all organ systems and of the psychosocial situation. Specifically, right ventricular function and risk of right ventricular failure should be evaluated before planning destination MCSD implantation. Treatment will focus on prompt recovery from MCSD implantation, maintaining optimal treatment for heart failure, and preventing/treating MCSD complications, including infection, bleeding, coagulopathy, right heart failure, and device dysfunction. MCSD programs should be organized as an advanced heart failure center directed by specialized heart failure cardiologists, surgeons expert at implant and management of MCSD, specialized nurses, social workers, psychologists, financial experts, and physical therapists. MCSD practice is based on a patient-centered theory, with an appropriate understanding of the respective roles of the physician and the patient during their iterative encounters in which the patient is an autonomous person making responsible personal health decisions while the health care team is providing continued expert and empathic counseling about various options, based on systematic outcomes research (eg, by participation in the Interagency Registry for Mechanically Assisted Circulatory Support - MCSD database ).

References

Nieminen M, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola V . EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006; 27(22):2725-36. DOI: 10.1093/eurheartj/ehl193. View

Lazar R, Shapiro P, Jaski B, Parides M, Bourge R, Watson J . Neurological events during long-term mechanical circulatory support for heart failure: the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experience. Circulation. 2004; 109(20):2423-7. DOI: 10.1161/01.CIR.0000129414.95137.CD. View

Poston R, Husain S, Sorce D, Stanford E, Kusne S, Wagener M . LVAD bloodstream infections: therapeutic rationale for transplantation after LVAD infection. J Heart Lung Transplant. 2003; 22(8):914-21. DOI: 10.1016/s1053-2498(02)00645-9. View

Letsou G, Shah N, Gregoric I, Myers T, Delgado R, Frazier O . Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant. 2005; 24(1):105-9. DOI: 10.1016/j.healun.2003.10.018. View

Schoolwerth A, Sica D, Ballermann B, Wilcox C . Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart.... Circulation. 2001; 104(16):1985-91. DOI: 10.1161/hc4101.096153. View

Birks E, Tansley P, Yacoub M, Bowles C, Hipkin M, Hardy J . Incidence and clinical management of life-threatening left ventricular assist device failure. J Heart Lung Transplant. 2004; 23(8):964-9. DOI: 10.1016/j.healun.2004.06.024. View

Cesario D, Dec G . Implantable cardioverter-defibrillator therapy in clinical practice. J Am Coll Cardiol. 2006; 47(8):1507-17. DOI: 10.1016/j.jacc.2005.09.077. View

Goldstein D, Zucker M, Arroyo L, Baran D, McCarthy P, Loebe M . Safety and feasibility trial of the MicroMed DeBakey ventricular assist device as a bridge to transplantation. J Am Coll Cardiol. 2005; 45(6):962-3. DOI: 10.1016/j.jacc.2004.12.020. View

Anversa P, Kajstura J, Leri A . If I can stop one heart from breaking. Circulation. 2007; 115(7):829-32. DOI: 10.1161/CIRCULATIONAHA.106.682195. View

10.

Siegenthaler M, Westaby S, Frazier O, Martin J, Banning A, Robson D . Advanced heart failure: feasibility study of long-term continuous axial flow pump support. Eur Heart J. 2005; 26(10):1031-8. DOI: 10.1093/eurheartj/ehi163. View

11.

Mancini D, Burkhoff D . Mechanical device-based methods of managing and treating heart failure. Circulation. 2005; 112(3):438-48. DOI: 10.1161/CIRCULATIONAHA.104.481259. View

12.

Ogata K, Platt J . Potential applications and prospects for cardiac xenotransplantation. J Heart Lung Transplant. 2004; 23(5):515-26. DOI: 10.1016/j.healun.2003.07.007. View

13.

Cleland J, Daubert J, Erdmann E, Freemantle N, Gras D, Kappenberger L . The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005; 352(15):1539-49. DOI: 10.1056/NEJMoa050496. View

14.

George I, Xydas S, Topkara V, Ferdinando C, Barnwell E, Gableman L . Clinical indication for use and outcomes after inhaled nitric oxide therapy. Ann Thorac Surg. 2006; 82(6):2161-9. DOI: 10.1016/j.athoracsur.2006.06.081. View

15.

Bardy G, Lee K, Mark D, Poole J, Packer D, Boineau R . Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005; 352(3):225-37. DOI: 10.1056/NEJMoa043399. View

16.

Gregoric I, Harting M, Kosir R, Patel V, Ksela J, Messner G . Percutaneous tracheostomy after mechanical ventricular assist device implantation. J Heart Lung Transplant. 2005; 24(10):1513-6. DOI: 10.1016/j.healun.2004.12.109. View

17.

Holman W, Park S, Long J, Weinberg A, Gupta L, Tierney A . Infection in permanent circulatory support: experience from the REMATCH trial. J Heart Lung Transplant. 2004; 23(12):1359-65. DOI: 10.1016/j.healun.2003.09.025. View

18.

Morgan J, Park Y, Oz M, Naka Y . Device related infections while on left ventricular assist device support do not adversely impact bridging to transplant or posttransplant survival. ASAIO J. 2003; 49(6):748-50. DOI: 10.1097/01.mat.0000093961.78341.5c. View

19.

Schmid C, Tjan T, Etz C, Schmidt C, Wenzelburger F, Wilhelm M . First clinical experience with the Incor left ventricular assist device. J Heart Lung Transplant. 2005; 24(9):1188-94. DOI: 10.1016/j.healun.2004.08.024. View

20.

Smith N, Bresee J, Shay D, Uyeki T, Cox N, Strikas R . Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55(RR-10):1-42. View